Skip to main content

Main menu

  • Home
  • Content
    • Current issue
    • Past issues
    • Early releases
    • Collections
    • Sections
    • Blog
    • Infographics & illustrations
    • Podcasts
    • COVID-19 Articles
  • Authors & Reviewers
    • Overview for authors
    • Submission guidelines
    • Submit a manuscript
    • Forms
    • Editorial process
    • Editorial policies
    • Peer review process
    • Publication fees
    • Reprint requests
    • Open access
    • Patient engagement
  • Members & Subscribers
    • Benefits for CMA Members
    • CPD Credits for Members
    • Subscribe to CMAJ Print
    • Subscription Prices
    • Obituary notices
  • Alerts
    • Email alerts
    • RSS
  • JAMC
    • À propos
    • Numéro en cours
    • Archives
    • Sections
    • Abonnement
    • Alertes
    • Trousse média 2023
  • CMAJ JOURNALS
    • CMAJ Open
    • CJS
    • JAMC
    • JPN

User menu

Search

  • Advanced search
CMAJ
  • CMAJ JOURNALS
    • CMAJ Open
    • CJS
    • JAMC
    • JPN
CMAJ

Advanced Search

  • Home
  • Content
    • Current issue
    • Past issues
    • Early releases
    • Collections
    • Sections
    • Blog
    • Infographics & illustrations
    • Podcasts
    • COVID-19 Articles
  • Authors & Reviewers
    • Overview for authors
    • Submission guidelines
    • Submit a manuscript
    • Forms
    • Editorial process
    • Editorial policies
    • Peer review process
    • Publication fees
    • Reprint requests
    • Open access
    • Patient engagement
  • Members & Subscribers
    • Benefits for CMA Members
    • CPD Credits for Members
    • Subscribe to CMAJ Print
    • Subscription Prices
    • Obituary notices
  • Alerts
    • Email alerts
    • RSS
  • JAMC
    • À propos
    • Numéro en cours
    • Archives
    • Sections
    • Abonnement
    • Alertes
    • Trousse média 2023
  • Visit CMAJ on Facebook
  • Follow CMAJ on Twitter
  • Follow CMAJ on Pinterest
  • Follow CMAJ on Youtube
  • Follow CMAJ on Instagram
Letters
Open Access

Systemic absorption of intranasal corticosteroids may occur and can potentially affect the hypothalamic–pituitary–adrenal axis

Gregory A. Kline, Christopher J. Symonds and Daniel T. Holmes
CMAJ March 22, 2021 193 (12) E426; DOI: https://doi.org/10.1503/cmaj.78162
Gregory A. Kline
Clinical professor, Medicine/Endocrinology, University of Calgary, Calgary, Alta.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Christopher J. Symonds
Clinical associate professor, Medicine/Endocrinology, University of Calgary, Calgary, Alta.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Daniel T. Holmes
Clinical professor, Department of Pathology and Lab Medicine, University of British Columbia, Vancouver, BC
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site

In their recent CMAJ Practice article on intranasal corticosteroids, Drs. Fowler and Sowerby1 stated that this therapy is not associated with hypothalamic–pituitary–adrenal (HPA) axis suppression. However, scenarios exist in which suppression may occur; therefore, some additional details may be useful. In support of their statement, the authors cited only a review article that, in turn, cited another review article and other small, older studies. Most studies looking at the association between intranasal corticosteroid use and HPA axis suppression have had major design flaws, namely small numbers; use of presently outdated and less accurate cortisol assays; collection of adrenal tests as an exploratory secondary outcome; lack of differentiation between different types, doses and durations of glucocorticoids; and lack of clinically relevant data.

A 2015 systematic review and meta-analysis of primary data, using appropriate inclusion, exclusion and stratification criteria showed that 4.2% (95% confidence interval 0.5%–28.9%) of patients using intranasal steroids could have adrenal suppression when a biochemical definition was used.2 The risk is likely increased with longer duration of use and with higher doses but is likely less than what is observed with inhaled steroids for asthma treatment. However, in combination with medications that inhibit cytochrome P-450 3A4 (CYP3A4 inhibitors), which will slow systemic glucocorticoid metabolism, intranasal steroids may even cause Cushing syndrome,3,4 with rebound adrenal insufficiency after treatment is stopped, which emphasizes5 their potential for systemic absorption.

Although adverse clinical sequelae may be uncommon, modern laboratories’ use of more specific cortisol immunoassays or mass spectrometry can show a low basal cortisol level when measured in a patient who is using intranasal or inhaled steroids, particularly in those receiving highly active antiretroviral therapy or azole antifungal agents. It is a common mistake to interpret this as “adrenal insufficiency” in need of replacement therapy instead of simply evidence that the synthetic glucocorticoid does indeed have systemic absorption and may be suppressing the HPA axis. A low level of serum cortisol in a patient using exogenous glucocorticoids is not an indicator of future HPA axis suppression, delayed recovery or clincial adrenal insufficiency after treatment is stopped. As intranasal steroids may be absorbed systemically and affect the HPA axis; decisions about when and how to stop such therapy should be carefully considered, in particular in patients undergoing treatment with CYP3A4 inhibitors.

Footnotes

  • Competing interests: None declared.

This is an Open Access article distributed in accordance with the terms of the Creative Commons Attribution (CC BY-NC-ND 4.0) licence, which permits use, distribution and reproduction in any medium, provided that the original publication is properly cited, the use is noncommercial (i.e., research or educational use), and no modifications or adaptations are made. See: https://creativecommons.org/licenses/by-nc-nd/4.0/

References

    1. Fowler J,
    2. Sowerby LJ
    . Using intranasal corticosteroids. CMAJ 2021;193:E47–47.
    1. Broersen LHA,
    2. Pereira AM,
    3. Jørgensen JOL,
    4. et al
    . Adrenal insufficiency in corticosteroids use: systematic review and meta-analysis. J Clin Endocrinol Metab 2015;100:2171–80.
    1. Hillebrand-Haverkort ME,
    2. Prummel MF,
    3. ten Veen JH
    . Ritonavir-induced Cushing’s syndrome in a patient treated with nasal fluticasone. AIDS 1999;13:1803–1803.
    1. Chen F,
    2. Kearney T,
    3. Robinson S,
    4. et al
    . Cushing’s syndrome and severe adrenal suppression in patients treated with ritonavir and inhaled nasal fluticasone. Sex Transm Infect 1999;75:274–274.
    1. Veilleux O,
    2. Lee TC,
    3. McDonald EG
    . Rebound adrenal insufficiency after withdrawal of ritonavir in a 65-year-old man using inhaled budesonide. CMAJ 2017;189:E1188–91.

Content

  • Current issue
  • Past issues
  • Collections
  • Sections
  • Blog
  • Podcasts
  • Alerts
  • RSS
  • Early releases

Information for

  • Advertisers
  • Authors
  • Reviewers
  • CMA Members
  • CPD credits
  • Media
  • Reprint requests
  • Subscribers

About

  • General Information
  • Journal staff
  • Editorial Board
  • Advisory Panels
  • Governance Council
  • Journal Oversight
  • Careers
  • Contact
  • Copyright and Permissions
  • Accessibiity
  • CMA Civility Standards
CMAJ Group

Copyright 2023, CMA Impact Inc. or its licensors. All rights reserved. ISSN 1488-2329 (e) 0820-3946 (p)

All editorial matter in CMAJ represents the opinions of the authors and not necessarily those of the Canadian Medical Association or its subsidiaries.

To receive any of these resources in an accessible format, please contact us at CMAJ Group, 500-1410 Blair Towers Place, Ottawa ON, K1J 9B9; p: 1-888-855-2555; e: cmajgroup@cmaj.ca

Powered by HighWire